Free Trial

CureVac Q2 2023 Earnings Report

CureVac logo
$2.87 -0.12 (-4.01%)
(As of 12/20/2024 05:31 PM ET)

CureVac EPS Results

Actual EPS
-$0.33
Consensus EPS
-$0.28
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

CureVac Revenue Results

Actual Revenue
$8.25 million
Expected Revenue
$14.89 million
Beat/Miss
Missed by -$6.64 million
YoY Revenue Growth
N/A

CureVac Announcement Details

Quarter
Q2 2023
Time
N/A
URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

CureVac Earnings Headlines

Leerink Partners Sticks to Their Hold Rating for CureVac (CVAC)
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
CureVac Reports Significant Revenue Growth Amid Strategic Restructuring
See More CureVac Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CureVac? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CureVac and other key companies, straight to your email.

About CureVac

CureVac (NASDAQ:CVAC) N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

View CureVac Profile

More Earnings Resources from MarketBeat

Upcoming Earnings